Amgen Sees Acceleration In US Biosimilars Market

Landscape Is ‘Advancing Faster Than EU During A Comparable Period’, Report Indicates

 
• By Dave Wallace

The US marketplace for biosimilars is accelerating faster than the EU at a similar point in its existence, based on approval rates, Amgen has observed in a preview of its 2022 trends in biosimilars report that also offers new data on pricing and uptake.

Dial years acceleration speedometer
As the years go on, US biosimilar uptake is accelerating • Source: Shutterstock

More from Biosimilars

More from Products